Boston Scientific Is Maintained at Buy by TD Cowen
TD Cowen Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $110
TD Cowen Adjusts Price Target on Boston Scientific to $110 From $100, Maintains Buy Rating
Boston Scientific Is Maintained at Overweight by Wells Fargo
Boston Scientific Analyst Ratings
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $100
Citi Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $107
CICC Initiates Boston Scientific at Outperform With $116 Price Target
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $98
Boston Scientific's Promising Clinical Trials and Innovative Approaches Justify Buy Rating
Boston Scientific Is Maintained at Buy by Canaccord Genuity
Boston Scientific Analyst Ratings
CCORF Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $101
Piper Sandler Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $95
Piper Sandler Sticks to Their Buy Rating for Boston Scientific (BSX)
Needham Maintains Boston Scientific(BSX.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Ventyx Biosciences (VTYX)
Boston Scientific Analyst Ratings
Piper Sandler Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $95
Piper Sandler Releases a Buy Rating on Boston Scientific (BSX)